Table 1.

Clinical characteristics of the study participants.

	AllN = 220	Complex GHDN = 13	IsolatedGHD N = 109	SGAN = 79	Turner syndromeN = 19	P
Females/males	47%/53%	46%/54%	37%/63%	49%/51%	100%/0%	<0.0001
Birth weight (Z-score)	-0.91 ± 0.92	-0.53 ± 0.84	-0.62 ± 0.81	-1.35 ± 0.95	-0.91 ± 0.64	<0.0001
Birth length (Z score)	-1.27 ± 0.90	-0.84 ± 0.68	-0.94 ± 0.85	-1.76 ± 0.82	-1.35 ± 0.64	<0.0001
Gestational age (weeks)	38.2 ± 3.0	38.9 ± 2.2	38.8 ± 1.8	37.2 ± 3.9	38.3 ± 2.9	0.095
Midparental height (Z-score)	-0.45 ± 1.7	-0.32 ± 1.60	-0.12 ± 1.59	-0.72 ± 1.78	-1.68 ± 1.19	0.0016
Age at treatment onset (yrs)	9.8 ± 3.7	11.1 ± 4.4	10.5 ± 3.4	9.0 ± 3.4	7.8 ± 4.3	0.0007
Height at T0 (Z score)	-2.28 ± 0.92	-1.71 ± 1.36	-2.05 ± 0.89	-2.66 ± 0.64	-2.51 ± 1.11	0.0001
Weight at T0 (Z-score))	-1.32 ± 1.26	-0.02 ± 1.84	-1.04 ± 1.26	-2.00 ± 0.75	-1.01 ± 1.12	0.3545
BMI at T0 (Z-score)	-0.24 ± 1.50	0.95 ± 1.50	-0.01 ± 1.44	-0.99 ± 1.28	0.59 ± 1.29	0.0001
Puberty (no/yes)	86%/14%	64%/36%	85%/15%	90%/10%	94%/6%	0.0859
Mean rhGH dose (mg/kg.d)*	0.04 ± 0.01	0.03 ± 0.01	0.03 ± 0.01	0.04 ± 0.01	0.04 ± 0.01	0.0003
% of doses in a given range (mg/kg/d)
<0.03	48%	51%	55%	44%	29%	0.0025
0.03 to 0.045	42%	37%	40%	43%	54%	0.214
>0.45	10%	13%	5%	13%	17%	0.0129

*The mean daily rhGH dose was the dose truly received.